Skip to main navigation

    North America

    • United States
      • English
    • Canada
      • English
      • Français
  • Investors
    • Events & Presentations
    • Financials & Filings
    • Stock Information
    • Investor FAQs
    • Contact Us
  • Newsroom
  • Careers
    • Job Openings

    North America

    • United States
      • English
    • Canada
      • English
      • Français
  • Areas of Focus
    • Cardiometabolic
    • Hypertriglyceridemia
    • Dyslipidemia
    • Cardiovascular Disease
    • Pulmonary
    • Inflammatory Pulmonary Diseases
    • Muco-obstructive
    • Idiopathic Pulmonary Fibrosis
  • Our Medicines
  • Pipeline
  • Science & Innovation
    • Partnerships
    • Publications
    • Clinical Trials
  • Patients & Caregivers
    • What is RNAi?
    • Patient Centricity & Advocacy
    • Patient Stories
    • FCS Patient Insights
    • Expanded Access Programs
  • About
    • Leadership Team
    • Corporate Governance
  • Investors
    • Events & Presentations
    • Financials & Filings
    • Stock Information
    • Investor FAQs
    • Contact Us
  • Newsroom
  • Careers
    • Job Openings
Banner Image Banner Image

Event Details

Home / Investors / Events & Presentations/

AsiaTIDES: Oligonucleotide and Peptide Therapeutics

AsiaTIDES: Oligonucleotide and Peptide Therapeutics

Feb 27 - Mar 1, 2018 12:00 AM EST

Supporting Materials

Arrowhead’s TRiM™ Delivery System – Potent, Modular, and Versatile for RNAi Bruce D. Given, M.D., Chief Operating Officer 6.3 MB
Recent Advances in RNAi Therapeutics at Arrowhead Pharmaceuticals Zhen Li, Ph.D., SVP Chemistry and Manufacturing 8.1 MB

Location

Kyoto, Japan
  • Email Alerts
  • Download Library
  • RSS Feeds
  • Print Page
  • Search Investors

Footer Navigation

  • Areas of Focus
  • Our Medicines
  • Pipeline
  • Science & Innovation
  • Patients & Caregivers
  • About
  • Twitter
  • LinkedIn
  • Privacy Policy
  • Cookie Policy
  • Terms of Use
  • Sitemap
  • Contact Us
  • Safety Reporting

Copyright © Arrowhead Pharmaceuticals Inc.